MYC (Ab-58) Antibody

What epitope does the MYC (Ab-58) Antibody recognize and how does this differ from other c-Myc antibodies?

MYC (Ab-58) Antibody recognizes a peptide sequence around amino acids 56-60 (L-P-T-P-P) derived from Human Myc protein . This differs from many commercially available c-Myc antibodies that target either the phosphorylated T58 residue or the C-terminal region (such as the commonly used 9E10 clone that targets residues 408-438) . The epitope recognition is critical because:

• The antibody detects endogenous levels of total Myc protein regardless of phosphorylation status

• Unlike phospho-specific antibodies (like those targeting phospho-T58), MYC (Ab-58) provides information about total Myc protein expression rather than specific post-translational modifications

• When designing experiments requiring multiple Myc antibodies, combining MYC (Ab-58) with phospho-specific antibodies can provide complementary data about both total expression and specific modifications

What are the validated applications for MYC (Ab-58) Antibody and what controls should be included?

The MYC (Ab-58) Antibody has been validated for the following applications:

• Western Blotting (WB)

• Immunohistochemistry (IHC)

When using this antibody, appropriate controls should include:

• Positive control: Cell lines known to express c-Myc (such as most rapidly proliferating cancer cell lines)

• Negative control: Cells with c-Myc knockdown/knockout or tissues with minimal c-Myc expression

• Blocking peptide control: When available, pre-incubation of the antibody with the immunizing peptide should eliminate specific signal, as demonstrated with other Myc antibodies

• Loading control: When performing Western blotting, include housekeeping proteins (β-actin, GAPDH) for normalization

What are the optimal storage and handling conditions for maintaining MYC (Ab-58) Antibody activity?

For optimal antibody performance:

• Store at -20°C for long-term preservation (recommended for periods exceeding one month)

• Store at 4°C for short-term use (up to one month)

• Avoid repeated freeze-thaw cycles as this can degrade antibody performance

• The antibody is supplied at 1.0mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol

• Allow the antibody to equilibrate to room temperature before opening the vial to prevent condensation, which can dilute or contaminate the solution

What is the recommended protocol for using MYC (Ab-58) Antibody in Western blotting applications?

For optimal Western blotting results with MYC (Ab-58) Antibody:

• Sample preparation:

  • Lyse cells in RIPA buffer containing protease inhibitors

  • The expected molecular weight of c-Myc is approximately 49 kDa (calculated MW: 48804)

• Gel electrophoresis and transfer:

  • Separate 20-50 μg of total protein by SDS-PAGE (10-12% gel)

  • Transfer to PVDF or nitrocellulose membrane

• Blocking and antibody incubation:

  • Block membrane with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Dilute primary antibody (MYC (Ab-58)) at 1:1000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3 times with TBST, 5 minutes each

  • Incubate with HRP-conjugated secondary antibody (anti-rabbit) at 1:2000-1:5000 for 1 hour at room temperature

  • Wash 3 times with TBST, 5 minutes each

  • Develop using ECL substrate and image

• Expected results:

  • A specific band at approximately 49 kDa representing c-Myc protein

  • Signal intensity will vary based on cell type and experimental conditions

How can I optimize immunohistochemistry protocols using MYC (Ab-58) Antibody?

For immunohistochemistry applications:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin

  • Embed in paraffin and section at 4-6 μm thickness

  • Deparaffinize and rehydrate sections

• Antigen retrieval:

  • Perform heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Boil for 15-20 minutes followed by cooling to room temperature

• Staining procedure:

  • Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

  • Block non-specific binding with 5% normal goat serum for 1 hour

  • Incubate with primary antibody at 1:50-1:200 dilution overnight at 4°C

  • Apply appropriate detection system (e.g., HRP-polymer)

  • Develop with DAB substrate

  • Counterstain, dehydrate, and mount

• Controls and validation:

  • Include both positive control tissue (e.g., lymphoma samples with known c-Myc expression) and negative control tissue

  • For antibody validation, prepare a slide without primary antibody

  • Consider comparing staining patterns with phospho-specific Myc antibodies on serial sections

How do I interpret results comparing total c-Myc detection (using MYC (Ab-58)) versus phospho-T58 specific antibodies?

When comparing total c-Myc with phosphorylated forms:

What are the common technical issues when using MYC (Ab-58) Antibody and how can they be addressed?

Common issues and troubleshooting approaches:

• High background in immunostaining:

  • Increase blocking time or concentration of blocking reagent

  • Reduce primary antibody concentration

  • Ensure adequate washing steps (at least 3×5 minutes between incubations)

  • For IHC, consider using protein-free blocking buffers if the tissue has endogenous biotin

• Weak or no signal in Western blotting:

  • Increase protein loading (30-50μg total protein)

  • Optimize antibody concentration (try 1:500 instead of 1:1000)

  • Ensure transfer efficiency by staining membrane with Ponceau S

  • Verify sample preparation (ensure protease inhibitors were used)

  • Consider more sensitive detection methods (e.g., ECL Plus or SuperSignal West Femto)

• Multiple bands or unexpected band sizes:

  • c-Myc can appear as multiple bands due to post-translational modifications

  • A lower molecular weight band (around 45 kDa) may represent a cleaved form

  • Higher molecular weight bands may indicate ubiquitination or other modifications

  • Use positive control lysates with known c-Myc expression to establish expected banding pattern

• Cross-reactivity concerns:

  • The antibody is validated for human, mouse, and rat samples

  • When testing in other species, perform careful validation with appropriate controls

  • Consider using blocking peptides to confirm specificity

How can MYC (Ab-58) Antibody be integrated into studies of c-Myc stability regulation through T58/S62 phosphorylation?

Advanced experimental design for studying c-Myc stability:

• Dual immunoblotting approach:

  • Use MYC (Ab-58) to determine total c-Myc levels

  • Use phospho-specific antibodies against T58 and S62 sites

  • Calculate phosphorylation ratios (phospho-signal/total protein) to determine relative phosphorylation states

• Stability assays:

  • Treat cells with cycloheximide to inhibit protein synthesis

  • Harvest cells at different time points (0, 15, 30, 60, 120 minutes)

  • Perform Western blotting with MYC (Ab-58) to monitor degradation rate

  • Compare degradation kinetics between experimental conditions

• Kinase manipulation experiments:

  • Inhibit GSK-3β (responsible for T58 phosphorylation) using small molecules like SB216763

  • Activate or inhibit ERK/MAPK pathway (responsible for S62 phosphorylation)

  • Monitor changes in total c-Myc levels with MYC (Ab-58)

  • Correlate with changes in phospho-T58 and phospho-S62 levels

• Data interpretation framework:

  • T58A mutation (preventing T58 phosphorylation) significantly increases c-Myc stability and oncogenic potential

  • S62A mutation impacts c-Myc stability differently, showing lower oncogenic potential in vitro

  • The T58A mutation leads to increased S62 phosphorylation and increased protein stability, whereas the S62A mutant lacks phosphorylation at both residues

What are the considerations for using MYC (Ab-58) Antibody in chromatin immunoprecipitation (ChIP) studies?

While MYC (Ab-58) is not specifically validated for ChIP, researchers considering this application should:

• Perform antibody validation for ChIP:

  • Test antibody specificity in your cell system using Western blotting first

  • Perform pilot ChIP experiments with positive control loci (known Myc-binding regions)

  • Include appropriate negative controls (IgG and negative loci)

• ChIP protocol considerations:

  • Optimize crosslinking conditions (1% formaldehyde for 10 minutes is standard)

  • Use sonication conditions that generate 200-500 bp DNA fragments

  • Pre-clear chromatin with protein A/G beads before antibody addition

  • Use 2-5 μg antibody per ChIP reaction

  • Include RNase and proteinase K digestion steps

• Data analysis approach:

  • Compare ChIP-qPCR results with established c-Myc target genes

  • Consider combining with MAX ChIP data, as MYC:MAX heterodimers are the functional transcriptional units

  • The CUT&RUN technique may offer higher sensitivity than traditional ChIP for c-Myc binding sites

• Expected results:

  • c-Myc binds to E-box motifs with the consensus sequence 5'-CAC[GA]TG-3'

  • Enrichment at promoters of growth-related genes

  • Co-occupancy with other transcription factors such as MAX is expected

How does MYC (Ab-58) Antibody perform in investigating c-Myc's role in cancer models compared to phospho-specific antibodies?

For comprehensive cancer research applications:

• Comparative analysis in cancer models:

  • MYC (Ab-58) provides baseline information about total c-Myc expression levels

  • Phospho-T58 antibodies reveal post-translational regulation that may be altered in cancer

  • Human tumors and cancer cell lines often display decreased T58 to increased S62 phosphorylation ratios, correlating with increased MYC protein stability

• Experimental design for cancer studies:

  • Compare normal tissues with tumor samples using both antibody types

  • Quantify the ratio of phospho-T58 to total c-Myc as a potential biomarker

  • In Burkitt lymphoma and AIDS-associated lymphomas, mutations around T58 and S62 are common, with T58I and T58A being predominant

• Functional studies in lymphoma models:

  • The Eμ-Myc mouse model shows that MAX deletion destabilizes MYC protein and abrogates lymphomagenesis

  • MYC T58A expression in mice leads to clonal T-cell lymphomas with 100% penetrance

  • MYC S62A mice develop lymphomas at a much lower penetrance

• Correlation table of MYC mutations and cancer phenotypes:

  MYC Variant	Phosphorylation Status	Cancer Phenotype	Reference
  Wild-type	Normal T58/S62 regulation	Baseline comparison
  T58A	Increased S62 phosphorylation	Aggressive T-cell lymphomas (100% penetrance)
  S62A	No phosphorylation at either site	Reduced lymphomagenesis
  T58I	No phosphorylation at either site	Common in Burkitt lymphoma

What methodologies can combine MYC (Ab-58) with c-Myc-tagged proteins for functional studies?

For researchers working with both endogenous c-Myc and tagged constructs:

• Dual detection strategies:

  • Use MYC (Ab-58) to detect endogenous c-Myc protein

  • Use tag-specific antibodies (such as 9E10 clone) to detect recombinant Myc-tagged proteins

  • This approach allows differentiation between endogenous and exogenous protein

• Functional rescue experiments:

  • Deplete endogenous c-Myc using siRNA/shRNA

  • Express siRNA-resistant Myc-tagged constructs (wild-type or mutants)

  • Use MYC (Ab-58) to confirm endogenous knockdown

  • Use tag-specific antibody to confirm expression of the tagged construct

• Safety considerations for c-Myc-tagged TCR therapy:

  • In adoptive T-cell therapy, T cells expressing myc-tagged TCRs can be selectively eliminated using tag-specific antibodies through complement-mediated lysis or antibody-dependent cell-mediated cytotoxicity

  • This provides a critical safety mechanism to terminate therapy if adverse effects occur

  • In vitro depletion efficiency ranges from 31-78% depending on the cell type and assay

How can researchers integrate MYC (Ab-58) Antibody into studies examining the MYC-MAX-MNT network?

For studying the complex MYC transcriptional network:

• Co-immunoprecipitation approaches:

  • Use MYC (Ab-58) to immunoprecipitate c-Myc protein complexes

  • Analyze co-precipitated proteins (MAX, MNT) by Western blotting

  • MAX loss has been shown to significantly reduce MYC protein levels

• Chromatin binding analysis:

  • Perform ChIP or CUT&RUN with antibodies against MYC, MAX, and MNT

  • Analyze genome-wide binding patterns to identify sites of co-occupancy

  • MAX was found to bind approximately 11,000 gene loci in B cells

  • There is substantial overlap between MAX, MYC, and MNT binding in B cells

• Functional outcomes:

  • The balance between MYC-MAX and MNT-MAX interactions shifts in premalignant B cells toward a MYC-driven transcriptional program

  • Cell cycle, E2F target, and MYC target gene sets are enriched in the MNT-MAX-MYC-bound gene populations

• Experimental design table for MAX deletion studies:

  Experiment	Method	Key Findings	Reference
  MAX deletion effect on MYC stability	Western blot	MAX loss reduces MYC protein levels
  Genome-wide binding	CUT&RUN sequencing	Significant overlap between MAX, MYC, and MNT binding
  Gene expression	RNA-seq	MAX loss leads to global down-regulation of MYC-activated genes
  Cancer model	Eμ-Myc mouse	MAX deletion completely abrogates lymphomagenesis

What are the methodological considerations when studying phosphorylation-dependent MYC degradation pathways?

For researchers investigating the complex degradation mechanisms of c-Myc:

• Sequential phosphorylation analysis:

  • Phosphorylation of c-Myc is a stepwise process: mitogens, mitosis, or cellular stress induce phosphorylation at S62, which serves as a priming site for GSK-3 phosphorylation of T58

  • Use phospho-specific antibodies to monitor this sequential process

  • Compare with total c-Myc levels detected by MYC (Ab-58)

• Ubiquitination assays:

  • T58 phosphorylation triggers recognition by FBXW7 E3 ubiquitin ligase

  • Design immunoprecipitation experiments using MYC (Ab-58) followed by ubiquitin detection

  • Treatment with proteasome inhibitors (MG132) can enhance detection of ubiquitinated species

• AKT/GSK3β pathway analysis:

  • Phosphorylation of AKT (p-AKT) and subsequent phosphorylation of GSK3β (p-GSK3β) at Ser9 increases MYC stability

  • Monitor these pathway components alongside MYC levels and phosphorylation status

  • Despite higher p-AKT and p-GSK3β levels in MAX knockout B cells, MYC levels were still reduced, suggesting MAX regulation of MYC stability operates through additional mechanisms

• Single-cell analysis:

  • Stain cells with MYC (Ab-58) and phospho-specific antibodies to obtain a snapshot of MYC stability at the single-cell level

  • This approach can reveal heterogeneity in MYC regulation within populations

  • Flow cytometry using MYC antibodies has been successfully employed to assess MYC protein levels in B cells